KPV: The Anti-Inflammatory Peptide Under FDA Review
Last reviewed and updated: May 5, 2026 — medically reviewed by Dr. Jonathann Kuo, MD.
Regulatory Update (April 2026): KPV is one of seven peptides scheduled for FDA Pharmacy Compounding Advisory Committee review on July 23, 2026. The committee will evaluate KPV for wound healing and inflammatory conditions and consider it for the Section 503A Bulk Drug Substances List. Read our full coverage: FDA to Review 7 Peptides for Compounding List in July 2026.
KPV is one of the shortest peptides in clinical research. It is just three amino acids long. Despite its tiny size, researchers have studied it for decades as an anti-inflammatory compound with potential applications in wound healing, inflammatory bowel disease, and skin conditions. The FDA is reviewing KPV for the Section 503A Bulk Drug Substances List in July 2026. Here is what the science shows and what the review could mean.
Interested in peptide therapy? Find vetted peptide therapy clinics near you.
| Topic | Detail |
|---|---|
| What it is | Tripeptide derived from the C-terminal of alpha-melanocyte stimulating hormone (α-MSH) |
| Sequence | Lysine-Proline-Valine (Lys-Pro-Val) |
| Research focus | Wound healing, inflammatory bowel disease, skin inflammation |
| Mechanism | Downregulates pro-inflammatory signaling pathways including NF-κB |
| Administration | Oral capsule, topical cream, or subcutaneous injection depending on indication |
| FDA status | Not approved; under PCAC review July 23, 2026 for 503A Bulks List inclusion |
What Is KPV?
KPV is a tripeptide made up of three amino acids: lysine, proline, and valine. It comes from the tail end of a larger molecule called alpha-melanocyte stimulating hormone (α-MSH). Alpha-MSH has well-documented anti-inflammatory properties. Researchers found that the KPV sequence alone preserves much of that anti-inflammatory activity while being smaller, more stable, and easier to deliver. That combination has made KPV a target for translational research into inflammatory conditions where larger biologics are not practical.
How KPV Works
Inflammation is driven in large part by a transcription factor called NF-κB. When cells sense damage or infection, NF-κB activates hundreds of inflammatory genes. KPV appears to interfere with NF-κB signaling. Studies published in journals including Gut have shown that KPV reduces inflammation in intestinal tissue by dampening this pathway. The peptide also has direct antimicrobial activity against certain bacteria and fungi, which may add a second layer of benefit in wound care applications.
Research in Inflammatory Bowel Disease
Some of the most studied applications of KPV are in inflammatory bowel disease. Animal models of colitis have shown that oral KPV reduces disease severity, improves weight recovery, and lowers inflammatory cytokine levels in colon tissue. Researchers have used nanoparticle delivery systems to protect KPV from digestion and target it to inflamed areas of the gut. Early human data is limited but the mechanism is biologically plausible, which is partly why KPV has continued to attract academic and clinical interest.
KPV for Wound Healing and Skin
Wound healing and inflammatory skin conditions are the specific uses the FDA identified for PCAC review. Research suggests KPV applied topically to wounds reduces inflammation and may accelerate tissue repair. Dermatology applications include chronic conditions such as eczema, acne, and hidradenitis suppurativa where inflammation drives much of the disease burden. Peptide clinics sometimes formulate KPV into topical creams for patients with stubborn inflammatory skin disorders that have not responded to standard therapy.
Administration Options
KPV is versatile in how it can be delivered. Oral capsules are common for gut-targeted indications, though bioavailability varies and some formulations use enteric coatings or lipid carriers to improve stability. Topical creams are used for skin and wound applications. Subcutaneous injection is used for systemic anti-inflammatory effect. The right route depends on the indication, the prescribing clinician’s protocol, and the compounding pharmacy’s formulation capabilities.
Safety and Side Effects
KPV has a reassuring safety profile in the research that exists. Its parent molecule, α-MSH, is a natural hormone the body produces daily. KPV itself is short, biodegradable, and does not accumulate in tissue. Reported side effects are minimal and include mild injection site reactions when used subcutaneously. As with any peptide used off-label, long-term safety data in human populations is limited. Clinicians typically screen patients for active infection, autoimmune disease, and pregnancy before starting KPV therapy.
Regulatory Status
KPV is not approved by the FDA for any indication. Compounding pharmacies have been filling prescriptions for KPV in various formulations, and the July 2026 PCAC review will directly address whether that practice falls within the Section 503A framework. A positive outcome would give clinicians and pharmacies clear regulatory standing. A negative outcome would likely end legal compounding of KPV under 503A. Until the review is complete, patients considering KPV should expect some uncertainty around long-term access.
Cost and Access
KPV is not covered by insurance. Cash-pay costs depend on the formulation. Oral capsules and topical creams often run $100 to $300 per month at typical therapeutic doses. Injectable formulations can cost more. Consultation and lab work from a peptide clinic add to the total cost. Always verify that your provider uses a licensed compounding pharmacy that follows USP 797 standards.
Finding a Provider
If you are interested in KPV therapy, look for a licensed clinician who has experience with peptide protocols and can order appropriate labs. Our peptide therapy directory lists verified clinics. For a broader overview of peptide therapy and how it fits into integrative medicine, see our complete guide to peptide treatments.
